Trial
NCT01397162
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Asthma
Intervention
Fluticasone propionate
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-23